King’s Medal Awarded to Canadian Neuromuscular Clinicans and Researchers
We are incredibly proud to share that several NMD4C investigators and collaborators from the Canadian neuromuscular community have been awarded a King Charles III’s Coronation Medal in recognition of their outstanding contributions and service in the neuromuscular field. This prestigious honour highlights their dedication, resilience, and impact in making a difference in the lives of people affected by NMDs.
We are pleased to congratulate the remarkable individuals, who received this recognition through nominations from Muscular Dystrophy Canada and the ALS Society of Canada for their outstanding achievements in the neuromuscular field, including NMD4C investigators and collaborators Drs Bernard Brais, Cynthia Gagnon, Rashmi Kothary, Lawrence Korngut, Alex MacKenzie, Colleen O’Connell, Kerri Schellenberg, Christen Shoesmith, Lorne Zinman, Robin Parks, and Guy Rouleau.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.